Maxim Group reiterated their buy rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research note released on Monday morning. Maxim Group currently has a $8.00 target price on the biopharmaceutical company’s stock.
“Inovio announced the initiation of a P2 study of DNA-based immunotherapy VGX-3100 for HPV-related (Human Papillomavirus) anal or perianal high-grade squamous intraepithelial lesions (HSIL). This is the third in-house” HPV- related study for VGX-3100; P3 in cervical dysplasia and P2 in high-grade vulvar lesions are both ongoing. In addition, partner MedImmune (AZN – NR) is developing MEDI0457 (VGX-3100 + IL-12 ) for H&N cancer.”,” the firm’s analyst commented.
A number of other equities analysts also recently weighed in on INO. ValuEngine raised shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research note on Friday. BidaskClub raised shares of Inovio Pharmaceuticals from a hold rating to a buy rating in a research note on Friday. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, May 16th. Finally, Royal Bank of Canada lifted their target price on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock an outperform rating in a research note on Thursday, March 15th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $11.59.
Inovio Pharmaceuticals opened at $4.81 on Monday, MarketBeat reports. The firm has a market cap of $453.90 million, a PE ratio of -4.41 and a beta of 2.52. Inovio Pharmaceuticals has a 52-week low of $3.76 and a 52-week high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.22). The business had revenue of $1.53 million for the quarter, compared to the consensus estimate of $7.50 million. Inovio Pharmaceuticals had a negative net margin of 292.06% and a negative return on equity of 72.04%. During the same period in the previous year, the business posted ($0.31) EPS. sell-side analysts forecast that Inovio Pharmaceuticals will post -1.36 EPS for the current fiscal year.
In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 103,750 shares of the firm’s stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $5.14, for a total value of $533,275.00. Following the completion of the sale, the chief executive officer now directly owns 2,395,557 shares in the company, valued at $12,313,162.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Weiner sold 9,000 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $4.91, for a total transaction of $44,190.00. Following the completion of the sale, the director now owns 758,956 shares of the company’s stock, valued at $3,726,473.96. The disclosure for this sale can be found here. Insiders sold 116,500 shares of company stock valued at $597,078 over the last 90 days. Corporate insiders own 9.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Inovio Pharmaceuticals by 10.5% during the fourth quarter. Geode Capital Management LLC now owns 833,627 shares of the biopharmaceutical company’s stock valued at $3,442,000 after buying an additional 79,001 shares during the last quarter. Guggenheim Capital LLC acquired a new position in shares of Inovio Pharmaceuticals during the first quarter valued at about $2,375,000. Deutsche Bank AG grew its holdings in shares of Inovio Pharmaceuticals by 247.7% during the fourth quarter. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company’s stock valued at $1,856,000 after buying an additional 320,376 shares during the last quarter. UBS Group AG grew its holdings in shares of Inovio Pharmaceuticals by 156.7% during the first quarter. UBS Group AG now owns 442,893 shares of the biopharmaceutical company’s stock valued at $2,086,000 after buying an additional 270,373 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Inovio Pharmaceuticals by 23.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 412,279 shares of the biopharmaceutical company’s stock valued at $1,942,000 after buying an additional 77,277 shares during the last quarter. Hedge funds and other institutional investors own 32.82% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.